Abstract

Epilepsy is one of the most common serious diseases of the central nervous system in the world. The effective system of pharmaceutical care for epileptic patients requires the involvement of appreciable budgetary financial resources. In order to determine the actual state of pharmaceutical care to the population, clinical and economic studies are used, the results of which allow to optimize the cost of pharmacotherapy and ensure the implementation of the constitutional rights of Ukrainian citizens to available medical and pharmaceutical care.
 The aim of the study was to conduct a clinical and economic analysis of pharmacotherapy of epilepsy.
 The object of the study was the data of 118 medical records of patients diagnosed with epilepsy, who were treating at specialized healthcare facilities. Evaluation of the degree of pharmacotherapy rationality in epileptic patients was taken using frequency, VEN, ABC analysis.
 The results of the investigation of patients’ medical records showed that 87 trade names of medications (76 international non-proprietary names of medications) were prescribed for epileptic patients. The total number of prescriptions is 918. The average number of prescriptions per patient is 7, which indicates polypragmasy. It was found that the leader in the number of appointments were carbamazepine – 11.11% of the total number of prescriptions and valproic acid – 3.49%. It is proved that in the structure of prescriptions for epileptic patients the part of medication with index V was 7.89%, which indicates a low degree of prescriptions compliance with healthcare standards. According to the results of the integrated ABC and VEN analysis, it was proved that among the groups A/V, A/E, A/N, the group A/V has the largest amount of expenditures – 36.38% of total cost. In general, group N accounts for 41.97% of total costs, which may indicate the irrational use of drugs in the provision of pharmaceutical care to epileptic patients.
 The results of clinical and economic analysis of medical records of epileptic patients allowed to identify features in the organization of pharmaceutical care, as well as to substantiate the main directions of improving pharmacotherapy of epileptic patients with limited budget funding for healthcare.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call